Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: liraglutide Clear all
Completed Phase 3 Interventional

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00333151
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, rosiglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
71
States / cities
Goodyear, Arizona • Colton, California • Concord, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
84
States / cities
Birmingham, Alabama • Coronado, California • Lancaster, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Recruiting Phase 2 Interventional

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

NCT07029009
View directory record Official record
Conditions
Maturity Onset Diabetes of the Young
Interventions
Liraglutide
Drug
Lead sponsor
Mansa
Other
Eligibility
10 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Los Alamitos, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

NCT02964247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

NCT01562678
View directory record Official record
Conditions
Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed No phase listed Observational

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

NCT02608853
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

NCT01832532
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
liraglutide
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

NCT02650206
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions
Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 69 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

NCT02696148
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Anaheim, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in Type 1 Diabetes

NCT01722240
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide 1.8mg, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jun 7, 2026, 4:39 AM EDT
Completed No phase listed Observational

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

NCT05162183
View directory record Official record
Conditions
Diabetes
Interventions
Glimepiride, Liraglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
3,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

NCT01800968
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Newark, Delaware • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

NCT00781937
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Jun 7, 2026, 4:39 AM EDT
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

NCT02973321
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899, Placebo, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 7, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jun 7, 2026, 4:39 AM EDT